Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Biocardia Inc

BCDA
Current price
3 USD -0.38 USD (-11.24%)
Last closed 3.38 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 6 462 305 USD
Yield for 12 month +15.83 %
1Y
3Y
5Y
10Y
15Y
BCDA
21.11.2021 - 28.11.2021

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. BioCardia, Inc. is based in Sunnyvale, California. Address: 320 Soquel Way, Sunnyvale, CA, United States, 94085

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

60 USD

P/E ratio

Dividend Yield

Current Year

+477 000 USD

Last Year

+1 352 000 USD

Current Quarter

+55 000 USD

Last Quarter

+13 000 USD

Current Year

+66 000 USD

Last Year

-10 549 000 USD

Current Quarter

-51 000 USD

Last Quarter

-92 000 USD

Key Figures BCDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -10 328 000 USD
Operating Margin TTM -4136.36 %
PE Ratio
Return On Assets TTM -132.67 %
PEG Ratio
Return On Equity TTM -703.62 %
Wall Street Target Price 60 USD
Revenue TTM 468 000 USD
Book Value -1.27 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY -14.1 %
Dividend Yield
Gross Profit TTM -7 482 000 USD
Earnings per share -7.05 USD
Diluted Eps TTM -7.05 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics BCDA

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History BCDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 30.05.2024
Dividend Date 06.06.2019

Stock Valuation BCDA

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 22.2956
Price Sales TTM 21.8512
Enterprise Value EBITDA -0.92
Price Book MRQ 10.6661

Financials BCDA

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators BCDA

For 52 weeks

3.2 USD 43.17 USD
50 Day MA 5.2 USD
Shares Short Prior Month 235 432
200 Day MA 6.89 USD
Short Ratio 1.65
Shares Short 20 989
Short Percent 1 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

449.78 USD Microsoft Corporation +4.08 (+0.92%)
Detailed analytics

ETF funds


S

SLICHA

203.20 CHF UBS SLI A-dis -1.46 (-0.64%)
Detailed analytics

Metals


Gold

2320.99 USD Gold -0.16 (-0.01%)
Detailed analytics